{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:42:19Z","timestamp":1785426139101,"version":"3.56.0"},"reference-count":30,"publisher":"Vilnius University Press","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AML"],"abstract":"<jats:p>Introduction: Undifferentiated uterine sarcoma (UUS) is a rare, aggressive uterine mesenchymal malignancy with poor prognosis, for which, evidence supporting metastasis-directed treatment strategies is limited.Case presentation: A 59-year-old woman underwent total hysterectomy with bilateral salpingo-oophorectomy (R0) for stage IB UUS in 2016, followed by adjuvant doxorubicin\u2013ifosfamide. Three years later, surveillance CT identified bilateral pulmonary metastases. Video-assisted thoracoscopic resection confirmed metastatic UUS, and stereotactic body radiotherapy (SBRT) was delivered to residual and subsequent lung lesions, achieving sustained local control without systemic therapy. The patient remained progression-free for almost three years. In 2024, follow-up imaging showed no active sarcoma but incidentally detected a left breast lesion; biopsy revealed invasive ductal carcinoma with mucinous features. She underwent breast-conserving surgery with sentinel lymph node biopsy (pT1N0(sn)), followed by adjuvant whole-breast radiotherapy and endocrine therapy with tamoxifen.Outcomes: At 8.5 years from UUS diagnosis and one year after breast cancer treatment, the patient remains alive with no evidence of recurrent or metastatic disease and with excellent performance status (ECOG 0).Conclusions: This case demonstrates prolonged, chemotherapy-free control of metastatic UUS using a metastasis-directed strategy combining surgery and SBRT, and highlights the importance of continued surveillance for secondary primary malignancies. It supports considering an oligometastatic treatment paradigm and multidisciplinary management in selected UUS patients despite the absence of prospective data.<\/jats:p>","DOI":"10.15388\/amed.2026.33.1.18","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:35:13Z","timestamp":1784698513000},"page":"204-213","source":"Crossref","is-referenced-by-count":0,"title":["When Local Beats Systemic: Durable Control of Metastatic Undifferentiated Uterine Sarcoma and Surveillance Uncovering a Second Primary"],"prefix":"10.15388","volume":"33","author":[{"given":"Ignas","family":"Lapeikis","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0069bkg23","id-type":"ROR","asserted-by":"publisher"}],"name":"Lithuanian University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vakar\u0117","family":"Baranauskyt\u0117","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0069bkg23","id-type":"ROR","asserted-by":"publisher"}],"name":"Lithuanian University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainius","family":"Jan\u010diauskas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0069bkg23","id-type":"ROR","asserted-by":"publisher"}],"name":"Lithuanian University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Pu\u017eauskien\u0117","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0069bkg23","id-type":"ROR","asserted-by":"publisher"}],"name":"Lithuanian University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Korobeinikova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0069bkg23","id-type":"ROR","asserted-by":"publisher"}],"name":"Lithuanian University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6097","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref0","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, et al, eds. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. IARC; 2014."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Benson C, Miah AB. Uterine sarcoma-current perspectives. Int J Womens Health. 2017;9:597-606. doi:10.2147\/IJWH.S117754","DOI":"10.2147\/IJWH.S117754"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rizzo A, Pantaleo MA, Saponara M, Nannini M. Current status of the adjuvant therapy in uterine sarcoma: a literature review. World J Clin Cases. 2019;7(14):1753-1763. doi:10.12998\/wjcc.v7.i14.1753","DOI":"10.12998\/wjcc.v7.i14.1753"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Tanner EJ, Garg K, Leitao MM Jr, Soslow RA, Hensley ML. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol. 2012;127(1):27-31. doi:10.1016\/j.ygyno.2012.06.030","DOI":"10.1016\/j.ygyno.2012.06.030"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145(1):61-70. doi:10.1016\/j.ygyno.2017.02.012","DOI":"10.1016\/j.ygyno.2017.02.012"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129-142. doi:10.1016\/j.critrevonc.2007.06.011","DOI":"10.1016\/j.critrevonc.2007.06.011"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131-139. doi:10.1016\/j.ygyno.2009.09.023","DOI":"10.1016\/j.ygyno.2009.09.023"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-423. doi:10.1016\/S1470-2045(14)70063-4","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Takano T, Niikura H, Ito K, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol. 2014;19(5):897-905. doi:10.1007\/s10147-013-0627-5","DOI":"10.1007\/s10147-013-0627-5"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lee TH, Kim HJ, Kim JH, et al. Treatment outcomes of stereotactic body radiation therapy for pulmonary metastasis from sarcoma: a multicenter, retrospective study. Radiat Oncol. 2023;18(1):68. doi:10.1186\/s13014-023-02255-y","DOI":"10.1186\/s13014-023-02255-y"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Baumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol. 2016;114(1):65-69. doi:10.1002\/jso.24268","DOI":"10.1002\/jso.24268"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Koivisto-Korander R, Sc\u00e9lo G, Ferro G, et al. Second primary malignancies among women with uterine sarcoma. Gynecol Oncol. 2012;126(1):30-35. doi:10.1016\/j.ygyno.2012.04.002","DOI":"10.1016\/j.ygyno.2012.04.002"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Pham ENB, van den Berg CB, Boere I, et al. Quality of life and survival in patients with uterine carcinosarcoma: a tertiary center observational study. Gynecol Oncol Rep. 2025;57:101679. doi:10.1016\/j.gore.2025.101679","DOI":"10.1016\/j.gore.2025.101679"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on Surveillance, Epidemiology, and End Results database. Int J Gynecol Cancer. 2016;26(6):1098-1104. doi:10.1097\/IGC.0000000000000720","DOI":"10.1097\/IGC.0000000000000720"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Abeler VM, R\u00f8yne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway: a histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355-364. doi:10.1111\/j.1365-2559.2009.03231.x","DOI":"10.1111\/j.1365-2559.2009.03231.x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Macuks R, Yildirim Y, Mancari R, et al. Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study. Arch Gynecol Obstet. 2023;308(3):981-988. doi:10.1007\/s00404-023-07057-x","DOI":"10.1007\/s00404-023-07057-x"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Lee CH, Mari\u00f1o-Enriquez A, Ou W, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641-653. doi:10.1097\/PAS.0b013e31824a7b1a","DOI":"10.1097\/PAS.0b013e31824a7b1a"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Lee CH, Ali RH, Rouzbahman M, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012;36(10):1562-1570. doi:10.1097\/PAS.0b013e31825fa931","DOI":"10.1097\/PAS.0b013e31825fa931"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Chiang S, Lee CH, Stewart CJR, et al. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Mod Pathol. 2017;30(9):1251-1261. doi:10.1038\/modpathol.2017.42","DOI":"10.1038\/modpathol.2017.42"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Binzer-Panchal A, Hardell E, Viklund B, et al. Integrated molecular analysis of undifferentiated uterine sarcomas reveals clinically relevant molecular subtypes. Clin Cancer Res. 2019;25(7):2155-2165. doi:10.1158\/1078-0432.CCR-18-2792","DOI":"10.1158\/1078-0432.CCR-18-2792"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Gremel G, Liew M, Hamzei F, et al. A prognosis-based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer. 2015;136(7):1608-1618. doi:10.1002\/ijc.29141","DOI":"10.1002\/ijc.29141"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Reed NS, Mangioni C, Malmstr\u00f6m H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an EORTC Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808-818. doi:10.1016\/j.ejca.2008.01.019","DOI":"10.1016\/j.ejca.2008.01.019"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013;24(4):1099-1104. doi:10.1093\/annonc\/mds545","DOI":"10.1093\/annonc\/mds545"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Hensley ML, Enserro D, Hatcher H, et al. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology\/Gynecologic Oncology Group study. J Clin Oncol. 2018;36(33):3324-3330. doi:10.1200\/JCO.18.00454","DOI":"10.1200\/JCO.18.00454"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Fidalgo JA, Ortega E, Ponce J, et al. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish Group for Research on Sarcomas (GEIS). Ther Adv Med Oncol. 2023;15:17588359231157645. doi:10.1177\/17588359231157645","DOI":"10.1177\/17588359231157645"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365. doi:10.1016\/j.annonc.2021.07.006","DOI":"10.1016\/j.annonc.2021.07.006"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Ray-Coquard I, Casali PG, Croce S, et al. ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas. Int J Gynecol Cancer. 2024;34(10):1499-1521. doi:10.1136\/ijgc-2024-005823","DOI":"10.1136\/ijgc-2024-005823"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Ann Surg. 1999;229(5):602-610. doi:10.1097\/00000658-199905000-00002","DOI":"10.1097\/00000658-199905000-00002"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment. Version 2.0 [Internet]. Ottawa (ON): CADTH; June 2022.","DOI":"10.51731\/cjht.2022.366"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Lee KD, Chen CY, Huang HJ, et al. Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period. BMC Cancer. 2015;15:393. doi:10.1186\/s12885-015-1426-3","DOI":"10.1186\/s12885-015-1426-3"}],"container-title":["Acta medica Lituanica"],"original-title":[],"link":[{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/43950\/42912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/43950\/42937","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/43950\/42912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:36:07Z","timestamp":1784716567000},"score":1,"resource":{"primary":{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/view\/43950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.15388\/amed.2026.33.1.18","relation":{},"ISSN":["2029-4174","1392-0138"],"issn-type":[{"value":"2029-4174","type":"electronic"},{"value":"1392-0138","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}